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We present a case of a Rendu-Osler-Weber disease patient with recurrent life threatening epistaxis demanding multiple blood
transfusions despite of repetitive endoscopic laser and electrocoagulations, endovascular embolisation, septodermoplasty, and
long-term intranasal dressings. As alternative treatment modalities repeatedly failed and the patient became almost permanently
dependent on nasal dressing, we performed a highly conformal intensity-modulated radiotherapy of the nasal cavity; a total dose
of 50Gy in 2Gy single fractions was applied. The therapy was very well tolerated, no acute toxicities occurred. Two weeks after
the last radiation dose had been applied, the nasal dressing could be removed without problems. Endoscopical control revealed an
almost avascular white mucosa without any trace of bleeding spots; previously existing hemangiomas and crusts had disappeared.
After a 1-year-follow up, the patient had no signiﬁcant recurrent epistaxis.
1.Introduction
This study is a case report of a 69-year-old lady with
Rendu-Osler-Weber disease who regularly attended the ENT
outpatient ward of the Inselspital Bern because of recurrent
severe epistaxis.
Hereditary hemorrhagic telangiectasia (HHT) or Rendu-
Osler-Weber disease is an autosomal dominant disorder
characterizedbyepistaxis,mucocutaneoustelangiectasesand
visceral arteriovenous malformations which aﬀects about 1
in 10,000 people [1]. There are hematologic, neurologic,
pulmonary, dermatologic and gastrointestinal complications
possible. Treatment is supportive and aims at preventing
complications [2]. A treatment guideline for epistaxis in
case of HHT recommends to do “as little as possible
f o ra sl o n ga sp o s s i b l e ”[ 3] whereas treatment modalities
include compression, topical antiﬁbrinolitic therapy, laser
coagulations, embolisations [4] and as an ultima ratio
radiotherapy [5, 6].
2. Case Presentation
The 69-years-old lady presented in good performance and
nutritional status. Because of the HHT-related recurrent
severe epistaxis causing anemia she had undergone multiple
sessions of blood transfusions, laser or elctrocoagulations,
septaldermatoplasticinterventionsandtransarterialemboli-
sations in the past.2 Case Reports in Medicine
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Figure 1: Radiotherapy planning I. IMRT plan with the planning target volume (PTV) in one CT cross section, red colours indicate a higher
dose; a steep dose gradient can be achieved by using ﬂuence modulation with a multi leaf collimator. Normal tissues are optimally spared.
Additional medical diagnoses were hypertension with
intermittent atrial ﬁbrillation, left ventricular hypertrophy,
pulmonary hypertension, visceral hypoperfusion, pyelo-
nephritis, an old portal venous thrombosis, fatty liver,
hyperuricemia and pulmonary embolism in 10/07. Many of
these diagnoses are pathogenetically related to the known
Rendu-Osler-Weber disease.
The patient reported that epistaxis ﬁrst occurred in her
adolescence (at the age of 16 years), approximately one to
two times per week and self-limiting, but showed a clear
progression over the years.
Transfusions were given for the ﬁrst time at the age of 40
years. At the age of 50 years epistaxis was not any more self-
limiting and occurred on average ﬁve times a week.
In the last four years she was therefore transfused
with more than one hundred erythrocyte concentrates and
had partly life-threatening haemoglobin levels. During this
period the haemoglobin levels were permanently low with
extreme values between 6.3g/dL and 11.8g/dL. Although the
patient has an arterial hypertension there seemed to be no
clear correlation between high blood pressures and severe
epistaxis attacks which can be deduced from an excellent
documentation by the patients’ husband.
The diagnosis Rendu-Osler-Weber disease was identiﬁed
in the 1980s with a strongly positive family history: her
father, two brothers and two of her three children also
showed/show symptoms of this illness.
Multiple endoscopic intranasal coagulations were per-
formed using neodymium, CO2 lasers, or bipolar coagu-
lation instruments. Failure in the control of the episodes
of massive epistaxis led to transarterial embolisation of
the maxillary, the facial and the sphenopalatine arteries
and attempts of septodermoplasty. Even these extended
procedures failed to prevent recurrence.
Two months after extensive neuroradiological emboli-
sation epistaxis was heavier than ever before and the
patient became almost entirely dependent on bilateral nasal
dressings, so all treatment modalities except radiotherapy
were exploited but had no permanent success.
Before we decided to perform an external radiotherapy
treatment it was discussed to employ brachytherapy. But as
merely contact to the nasal cavity caused heavy bleedings,
this modality was not considered as realistic option.
Radiotherapyplanningwasperformedusingthesolution
commercialized by VARIAN with the Eclipse treatment
planning system (TPS) and the Clinac accelerator (Figures
1 and 2). The planning CT was carried out with 3mm
step size, positioning was done with a thermoplastic mask
system (Figure 3). Intensity-modulated radiotherapy was
performed to optimally spare the surrounding normal
tissues. Altogether we administered 50Gy in 2Gy single
fractions (5 days per week), the therapy lasted ﬁve weeks
without interruptions. This conventional dosing schedule
was chosen to avoid possible late complications concerning
the organs at risk, the end dose was speciﬁed empirically.
The nose was tamponaded before the beginning of
the radiotherapy, the tamponade was changed once during
the radiotherapy course. To prevent bacterial infections
causing sinusitis the patient was daily treated by antibiotics
(Aminopenicillin combined with clavulan acid p. o. twice a
day). Two weeks after the last radiation fraction the nasal
dressing could be removed without problems in the OR.
Endoscopical control did reveal an almost avascular white
mucosa without any trace of bleeding spots, previously
existing hemangiomas and crusts had disappeared. Only
on the dorso-apical edge of the vast septal perforation we
c o u l dd e t e c ta3m mb l u i s hs p o ta sp o s s i b l es p o tf o ra no l d
hemangioma (Figures 4 and 5).
3. Discussion
The rationale to treat HHT-related severe recurrent epistaxis
with radiotherapy is to irreversibly destroy ﬁbrodysplastic
microvessels. The main mechanism as discussed in the
literature might be radiation-induced demise of endothelial
cells due to apoptosis. These cells are considered to be very
radiosensitive. The exact underlying molecular pathways of
endothelium dysfunction are not known so far [7, 8].
A bigger data set was acquired for intranasal brachyther-
apy for epistaxis in 43 patients with Rendu-Osler disease
treated between 1971–1991 at Henri Mondor Hospital. Dose
at one application ranged from 15–35Gy with a medianCase Reports in Medicine 3
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Figure 2: Radiotherapy planning II. Another CT section at the lower PTV boundary. Small insets show the complete extension of the PTV.
Figure 3:Radiotherapypositioning.Positioningofthepatientonthe
couch.Thethermoplasticmasksystemisusedtopreventthepatient
from moving during the treatment. The lines marked on the mask
system are used for the room lasers which are used to deﬁne the
exact positioning.
of 30Gy. The time to recurrence of signiﬁcant epistaxis
ranged from 6–178 months with a median of 24 months.
The dose prescribed did not correlate with control rate. The
only brachytherapy complication was septal perforation in 4
patients;inonethiswasaresultofrepeatednasalcoagulation
[6].
Pizzi et al. performed a similar but smaller study. The
dose given to the reference isodose was 30Gy. Complete
remission was seen in 4 patients. In 2 patients the response
haslasted18and32monthsand2othershadashorterfollow
Figure 4: Endoscopy of the right nasal cavity following removal
of the nasal dressing 2 weeks after the last radiotherapy showed a
vast septal perforation due to multiple endonasal interventions. A
3mmbluishspotatthedorsoapicalborderoftheseptalperforation
and very ﬁne teleangiectatic vessels were the only possible and now
inactive sites of the former extensive teleangiectatic lesions.
up. In 5 patients, a good response was obtained (mean: 58
months) [9].
Up to now, only very few trials or case reports are
reported on external irradiation [9–11].
Although a bigger data set is missing, external radiother-
apy seems to be an eﬀective treatment in this setting, but still
has to be used as a second line therapy as other treatment
modalities are faster and have potentially less side eﬀects.
But as a palliative treatment it may replace other treatment
methods, especially if they failed before [9].4 Case Reports in Medicine
Figure 5: Endoscopic picture of the right nasal cavity with anemic
and white nasal mucosa.
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